Try our Advanced Search for more refined results

Amphastar Pharmaceuticals, Inc, et al v. Momenta Pharmaceuticals, Inc, et al

  1. March 06, 2017

    Momenta Isn't Shielded From Antitrust Suit, 1st Circ. Says

    The First Circuit on Monday revived an antitrust suit alleging Momenta Inc. and Sandoz Inc. misled regulators about their patent on the industry test for an anticoagulant so they could squeeze rival Amphastar Pharmaceuticals Inc. out of the market with infringement claims, finding the district court erroneously applied the Noerr-Pennington doctrine.

  2. February 10, 2017

    1st Circ. Gauges Antitrust Immunity In Enoxaparin Row

    A three-judge First Circuit panel Thursday grilled opposing counsel on what exactly caused the injuries Amphastar alleged in a suit against rival Momenta over generic anticoagulant enoxaparin, and on whether Momenta is protected from the claims by a decades-old antitrust immunity doctrine.

  3. February 08, 2017

    1st Circ. To Size Up Antitrust Shield In Enoxaparin Row

    The First Circuit on Thursday will consider whether a lower court correctly held that drugmaker Momenta was immune from a suit from rival Amphastar over a generic anticoagulant in a case that could redefine the limits of a decades-old doctrine shielding free speech from antitrust claims.

  4. January 11, 2017

    Consumer Orgs Ask 1st Circ. To Ax Momenta Antitrust Shield

    Public interest groups urged the First Circuit on Tuesday to overturn a lower court's ruling that the Noerr-Pennington doctrine protects drugmaker Momenta from claims that it plotted with Sandoz to keep rival Amphastar from selling a generic version of the anticoagulant Lovenox, saying the court interpreted the doctrine too broadly.

  5. December 20, 2016

    Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity

    Amphastar Pharmaceuticals Inc. urged the First Circuit on Monday to revive its suit accusing Momenta Pharmaceuticals Inc. and Sandoz Inc. of trying to block a competing generic version of a blood clot medication, accusing the drugmakers of trying to rewrite a district court decision to hold on to their antitrust immunity.

  6. December 06, 2016

    Momenta Asks 1st Circ. To Affirm Enoxaparin Suit Immunity

    Momenta Pharmaceuticals Inc. asked the First Circuit Monday to uphold a determination that the company is immune from an antitrust action by Amphastar Pharmaceuticals Inc. over anticoagulant enoxaparin, saying a federal judge correctly held the Noerr-Pennington doctrine bars the claims.

  7. November 08, 2016

    FTC Asks 1st Circ. To Reverse Momenta Antitrust Win

    The Federal Trade Commission on Monday told the First Circuit that a lower court had incorrectly granted immunity to Momenta Pharmaceuticals Inc. from an antitrust suit by Amphastar Pharmaceuticals Inc. and asked the appeals court to reverse that decision.

  8. November 01, 2016

    Momenta Must Face Clot Drug Antitrust Row, 1st Circ. Told

    Misconduct by Momenta before a standard-setting organization that unknowingly led the group to create a standard for a blood-clot drug that requires the use of a company patent should not allow the generics maker to subsequently receive immunity from antitrust claims, generic rival Amphastar told the First Circuit on Monday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!